first-line - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 415880

<< First< Prev

Page of 20794

Next >Last >>

Select item 99990221.

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model

Mingye Zhao, Taihang Shao, Zhuoyuan Chi, Wenxi Tang

Front Public Health. 2023; 11: 1051484. Published online 2023 Feb 24. doi: 10.3389/fpubh.2023.1051484

PMCID:: PMC9999022

Article PDF–3.4M

Select item 106850242.

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice

P. Grivas, E. Grande, I.D. Davis, H.H. Moon, M.-O. Grimm, S. Gupta, P. Barthélémy, C. Thibault, S. Guenther, S. Hanson, C.N. Sternberg

ESMO Open. 2023 Dec; 8(6): 102050. Published online 2023 Oct 12. doi: 10.1016/j.esmoop.2023.102050

PMCID:: PMC10685024

Article PDF–622K

Select item 87338363.

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone

Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh

JAMA Netw Open. 2022 Jan; 5(1): e2142093. Published online 2022 Jan 5. doi: 10.1001/jamanetworkopen.2021.42093

PMCID:: PMC8733836

Article

Select item 89084054.

Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Aviv Pudipeddi, Yanna Ko, Sudarshan Paramsothy, Rupert W. Leong

Therap Adv Gastroenterol. 2022; 15: 17562848221080793. Published online 2022 Mar 8. doi: 10.1177/17562848221080793

PMCID:: PMC8908405

Article PDF–3.2M

Select item 107987635.

Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review

Haiyang Guo, Jun Zhang, Chao Qin, Hang Yan, Xinyue Luo, Haining Zhou

Medicine (Baltimore) 2024 Jan 19; 103(3): e36861. Published online 2024 Jan 19. doi: 10.1097/MD.0000000000036861

PMCID:: PMC10798763

Article PDF–611K

Select item 94122206.

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era

Nayan Lamba, Patrick A. Ott, J. Bryan Iorgulescu

JAMA Netw Open. 2022 Aug; 5(8): e2225459. Published online 2022 Aug 25. doi: 10.1001/jamanetworkopen.2022.25459

PMCID:: PMC9412220

Article

Select item 65169957.

First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension

Yu Jie Chen, Liang Jin Li, Wen Lu Tang, Jia Yang Song, Ru Qiu, Qian Li, Hao Xue, James M Wright, Cochrane Hypertension Group

Cochrane Database Syst Rev. 2018; 2018(11): CD008170. Published online 2018 Nov 14. doi: 10.1002/14651858.CD008170.pub3

PMCID:: PMC6516995

Article PDF–1.0M

Select item 88598668.

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer

Cochrane Database Syst Rev. 2022; 2022(2): CD012007. Published online 2022 Feb 21. doi: 10.1002/14651858.CD012007.pub2

PMCID:: PMC8859866

Article PDF–1.3M

Select item 79329429.

Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data

Ani John, Baiyu Yang, Roma Shah

Adv Ther. 2021; 38(3): 1552–1566. Published online 2021 Feb 4. doi: 10.1007/s12325-020-01617-2

PMCID:: PMC7932942

Article PDF–1.0M

Select item 1078535410.

A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

Hanqiao Shao, Mingye Zhao, Ai-Jia Guan, Taihang Shao, Dachuang Zhou, Guo Yu, Wenxi Tang

BMC Med. 2024; 22: 13. Published online 2024 Jan 12. doi: 10.1186/s12916-023-03238-2

PMCID:: PMC10785354

Article PDF–3.2M

Select item 651355911.

First‐line drugs for hypertension

James M Wright, Vijaya M Musini, Rupam Gill, Cochrane Hypertension Group

Cochrane Database Syst Rev. 2018; 2018(4): CD001841. Published online 2018 Apr 18. doi: 10.1002/14651858.CD001841.pub3

PMCID:: PMC6513559

Article PDF–1.1M

Select item 904654012.

Influential Factors, Treatment and Prognosis of Autoimmune Encephalitis Patients With Poor Response to Short-Term First-Line Treatment

Fei Liu, Bingbing Zhang, Teng Huang, Baojie Wang, Chunjuan Wang, Maolin Hao, Shougang Guo

Front Neurol. 2022; 13: 861988. Published online 2022 Apr 14. doi: 10.3389/fneur.2022.861988

PMCID:: PMC9046540

Article PDF–896K

Select item 1066570613.

Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study

Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang

Surg Open Sci. 2023 Dec; 16: 171–183. Published online 2023 Oct 31. doi: 10.1016/j.sopen.2023.10.008

PMCID:: PMC10665706

Article PDF–7.4M

Select item 865472714.

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

Anwen Xiong, Jiali Wang, Caicun Zhou

Front Oncol. 2021; 11: 757993. Published online 2021 Nov 25. doi: 10.3389/fonc.2021.757993

PMCID:: PMC8654727

Article PDF–417K

Select item 818735915.

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang

Sci Rep. 2021; 11: 12084. Published online 2021 Jun 8. doi: 10.1038/s41598-021-91657-7

Correction in:: Sci Rep. 2021; 11: 17646.

PMCID:: PMC8187359

Article PDF–1.3M

Select item 853544316.

Determinants of first-line antiretroviral treatment failure among adult patients on treatment in Mettu Karl Specialized Hospital, South West Ethiopia; a case control study

Sabit Zenu, Tariku Tesema, Mohammed Reshad, Endegena Abebe

PLoS One. 2021; 16(10): e0258930. Published online 2021 Oct 22. doi: 10.1371/journal.pone.0258930

PMCID:: PMC8535443

Article PDF–572K

Select item 752416917.

Managerial Competence of First-Line Nurse Managers in Public Hospitals in Indonesia

Joko Gunawan, Yupin Aungsuroch, Mary L Fisher, Anna M McDaniel, Colleen Marzilli

J Multidiscip Healthc. 2020; 13: 1017–1025. Published online 2020 Sep 25. doi: 10.2147/JMDH.S269150

PMCID:: PMC7524169

Article PDF–321K

Select item 852515718.

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

Jim Canet, Pascale Cony‐Makhoul, Sébastien Orazio, Edouard Cornet, Xavier Troussard, Marc Maynadié, Gabriel Étienne, Alain Monnereau

Cancer Med. 2021 Oct; 10(20): 6959–6970. Published online 2021 Sep 22. doi: 10.1002/cam4.4186

PMCID:: PMC8525157

Article PDF–686K

Select item 912287719.

Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer

Hironaga Satake, Yoshinori Kagawa, Eiji Shinozaki, Yoshinori Tanizawa, Long Jin, Zhihong Cai, Akitaka Makiyama

Adv Ther. 2022; 39(6): 2596–2613. Published online 2022 Apr 6. doi: 10.1007/s12325-022-02122-4

PMCID:: PMC9122877

Article PDF–1.4M

Select item 826884120.

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study

Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, Dimitrios Mavroudis, Epaminondas Samantas, Evangelos Georgios Fergadis, Helena Linardou, Panagiotis Katsaounis, Elias Athanasiadis, Michalis V. Karamouzis, George Pentheroudakis, Sofia Lampaki, Marios E. Froudarakis, Eleni-Isidora A. Perdikouri, Alvertos Somarakis, Foteini Papageorgiou, Zoe Paparepa, Aristeidis Nikolaou, Konstantinos N. Syrigos

Cancers (Basel) 2021 Jul; 13(13): 3172. Published online 2021 Jun 25. doi: 10.3390/cancers13133172

PMCID:: PMC8268841

Article PDF–2.2M

<< First< Prev

Page of 20794

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for first-line

Figure 3. Overall survival analysis in participants treated with first-line chemoimmunotherapy versus chemotherapy alone.

(A) Pooled HR for OS in patients with advanced NSCLC treated with first-line chemoimmunotherapy. (B) Pooled HR for OS in patients with advanced squamous NSCLC treated with first-line chemoimmunotherapy. (C) Pooled HR for OS in patients with advanced nonsquamous NSCLC treated with first-line chemoimmunotherapy. (D) Pooled HR for OS in patients with advanced NSCLC treated with PD-1 inhibitor (pembrolizumab) in combination with chemotherapy in the first-line setting. (E) Pooled HR for OS in patients with advanced NSCLC treated with PD-L1 inhibitor (atezolizumab) in combination with chemotherapy in the first-line setting. (F) Pooled HR for OS in PD-L1 negative patients with advanced NSCLC in the first-line setting. (G) Pooled HR for OS in PD-L1 low patients with advanced NSCLC in the first-line setting. (H) Pooled HR for OS in PD-L1 high patients with advanced NSCLC in the first-line setting.
HR: Hazard ratio; NSCLC: Non-small-cell lung cancer; OS: Overall survival; PD-1: Programmed death receptor 1; PD-L1: Programmed death ligand 1.

Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Future Sci OA. 2019 Oct;5(9):FSO421.
Figure 4. Progression-free survival analysis in participants treated with first-line chemoimmunotherapy versus standard chemotherapy regimen.

(A) Pooled HR for PFS in patients with advanced NSCLC treated with first-line chemoimmunotherapy. (B) Pooled HR for PFS in patients with advanced squamous NSCLC treated with first-line chemoimmunotherapy. (C) Pooled HR for PFS in patients with advanced nonsquamous NSCLC treated with first-line chemoimmunotherapy. (D) Pooled HR for PFS in patients with advanced NSCLC treated with PD-1 inhibitor (nivolumab or pembrolizumab) in combination with chemotherapy in the first-line setting. (E) Pooled HR for PFS in patients with advanced NSCLC treated with PD-L1 inhibitor (atezolizumab) in combination with chemotherapy in the first-line setting. (F) Pooled HR for PFS in PD-L1 negative patients with advanced NSCLC in the first-line setting. (G) Pooled HR for PFS in PD-L1 low patients with advanced NSCLC in the first-line setting. (H) Pooled HR for PFS in PD-L1 high patients with advanced NSCLC in the first-line setting. (I) Pooled HR for PFS in patients with EGFR and ALK mutated advanced NSCLC treated with atezolizumab.
HR: Hazard ratio; NSCLC: Non-small-cell lung cancer; OS: Overall survival; PD-1: Programmed death receptor 1; PD-L1: Programmed death ligand 1; PFS: Progression-free survival.

Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Future Sci OA. 2019 Oct;5(9):FSO421.
Figure 2. Overall Survival by Race and Treatment, First-Line Abiraterone vs First-Line Enzalutamide

Treatment groups correspond to abiraterone-based first-line regimens and first-line single-agent enzalutamide. Numbers at risk represented in Kaplan-Meier curves are scaled according to the propensity score analysis inverse probability of treatment weighting. OS indicates median overall survival; 1L, first line.

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone

JAMA Netw Open. 2022 Jan;5(1):e2142093.
Figure 3.

(a) Comparison of overall survival (OS) between patients with metastatic or recurrent, unresectable KRAS mutant NSCLC and a response to pemetrexed (partial or complete) in the first line of therapy and patients who received pemetrexed in the first line and did not respond. (b) Comparison of progression free survival (PFS) between patients with metastatic or recurrent, unresectable KRAS mutant NSCLC and a response to pemetrexed (partial or complete) in the first line of therapy and patients who received pemetrexed in the first line and did not respond. (c) Comparison of OS between patients with metastatic KRAS mutant NSCLC and a response to first line chemotherapy and patients who did not respond to first line chemotherapy. (d) Comparison of PFS between patients with metastatic KRAS mutant NSCLC and a response to first line chemotherapy and patients who did not respond to first line chemotherapy.

First line chemotherapy responsiveness and patterns of metastatic spread identify clinical syndromes present within advanced KRAS mutant non-small cell lung cancer with different prognostic significance

Clin Lung Cancer. ;19(6):531-543.